ROMINA MARINA SIMA, DRAGOS ALBU, ANTONIU CRINGU IONESCU, MIHAI DIMITRIU, MIHAI POPESCU, DANA-RODICA TOMESCU, RADU CHICEA, IULIANA CEAUSU, IOAN-IULIAN IORDACHE, MIRCEA-OCTAVIAN POENARU, ALEXANDRA MATEI, ALINA CALIN, LIANA PLES THE IMPACT OF ULIPRISTAL ACETATE (UPA) VERSUS DIENOGEST ON PAIN RELATED TO ENDOMETRIOMAS EVALUATED WITH VISUAL ANALOGUE SCALE (VAS) Visual analogue scale (VAS) is a psychometric scale applied to measure subjective characteristics. The purpose of our study was to evaluate the efficiency of Ulipristal acetate (UPA) compared with Dienogest for endometriomas related pain using VAS. We performed a randomized study on women with symptomatic endometriomas. The study was realized between January 2016–December 2018. The patients were randomized in two groups: Group A- that received UPA in doses of 5 mg daily for 12–13 weeks and Group B that received 2 mg Dienogest for 12–13 weeks. Each group received de VAS (Visual Analogue Scale) questionnaire before and after treatment. 70 women wereincluded in the study with 35 patients for each group. The age the mean age was 30.20 years. For Numeric Rating Scale before treatment in the group with UPA the median value was 6 (CI= 5.26, 6.51) and for group B the median was 5 (CI= 5.13, 5.66). After treatment for group A the median value was 4 (CI= 3.58, 4.29) and for group B the median value 4 (CI= 4.23, 4.6). For FRS before treatment in the group with UPA median value was 6 (CI= 5.87, 6.58) and for the group B median was 6 (CI= 6.16, 6.57). After treatment for group A the median value was 4 (CI= 4.12, 4.73) and for group B the median value 5 (CI= 4.9, 5.06). The pain significantly improved for group A. (p< 0.05) VAS represent a good method to evaluate the quality of pain for patients with endometriomas. The UPA and Dienogest treatment improve the VAS parameters with better results for UPA in the present study.
Keywords: endometriosis, VAS, dienogest, ulipristal, pain